Myrtelle Announces Presentation at the 5 th Annual Gene Therapy for Neurological Disorders Summit: Optimizing Gene Therapies Targeting the CNS to Deliver Safe & Efficacious Treatment Options For Neurological Disorder Patients
Wakefield, Mass., November 7, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a clinical-stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
This article is featured on another website.
Actym Therapeutics Expands Management Team with Key Appointments to Build Product Pipeline and Advance Clinical Development Strategies
Mary J. Janatpour, PhD, joins Actym as Chief Scientific Officer focused on expanding Actym’s pipeline Shouryadeep “Deep” Srivastava, MD, PhD, joins Actym as Senior Vice President of Clinical Development, leading Actym’s clinical activities BERKELEY, CA — June 25, 2024 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointments of […]
Actym Therapeutics Expands Management Team with Key Appointments to Build Product Pipeline and Advance Clinical Development Strategies
Mary J. Janatpour, PhD, joins Actym as Chief Scientific Officer focused on expanding Actym’s pipeline Shouryadeep “Deep” Srivastava, MD, PhD, joins Actym as Senior Vice President of Clinical Development, leading Actym’s clinical activities BERKELEY, CA — June 25, 2024 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointments of […]